Powered by: Motilal Oswal
2024-12-23 10:45:02 am | Source: Accord Fintech
Aurobindo Pharma rises as its step-down arm gets UK`s MHRA`s nod for Bevqolva

Aurobindo Pharma is currently trading at Rs. 1244.40, up by 3.70 points or 0.30% from its previous closing of Rs. 1240.70 on the BSE.

The scrip opened at Rs. 1265.00 and has touched a high and low of Rs. 1265.00 and Rs. 1238.80 respectively. So far 5037 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 959.05 on 14-Feb-2024.

Last one week high and low of the scrip stood at Rs. 1274.70 and Rs. 1202.70 respectively. The current market cap of the company is Rs. 72199.45 crore.

The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.72% and 6.46% respectively.

Aurobindo Pharma’s step-down subsidiary -- CuraTeQ Biologics s.r.o. has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version. Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins. 

Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here